|Mr. Shaun Edward Chilton||CEO & Exec. Director||893k||N/A||1968|
|Mr. Nicholas Keher||CFO & Director||N/A||N/A||N/A|
|Ms. Debra Ainge||Chief Operating Officer||N/A||N/A||N/A|
|Matt Parrish||Head of Investor Relations||N/A||N/A||N/A|
|Mr. David Bryant||Director of Corp. Devel.||N/A||N/A||N/A|
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Clinigen Group Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.